Advancis drug flunks trial

Shares of Advancis Pharmaceutical were sinking this morning after the drug developer announced its Amoxicillin PULSYS Phase III clinical trial for pharyngitis/tonsillitis due to strep throat failed to hit its primary endpoint. The trial compared Advancis' Amoxicillin PULSYS 775 mg tablet dosed once-daily for seven days to 250 mg of penicillin VK dosed four times daily for 10 days. According to top-line trial data, Amoxicillin PULSYS failed to demonstrate statistical non-inferiority to the comparator therapy in the primary endpoint: bacterial eradication at the post-therapy test-of-cure visit for patients who successfully completed the trial protocol. Advancis has been developing the therapy with Par.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.